Catalysts / ZURA
Upcoming FDA decisions and readouts we track for Zura Bio, each with the filing that announced it.
FreeBioList tracks 2 upcoming catalysts for Zura Bio (ZURA, listed on Nasdaq). Both concern Tibulizumab (ZB-106) (Hidradenitis suppurativa; Systemic sclerosis).
First on the list: the Phase 2 readout for Tibulizumab (ZB-106) (Hidradenitis suppurativa), guided by the company to Q4 2026. By stage, the upcoming rows are 2 Phase 2 readouts.
Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Zura Bio ZURA · Nasdaq | Tibulizumab (ZB-106) | Hidradenitis suppurativa | Q4 2026 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| Zura Bio ZURA · Nasdaq | Tibulizumab (ZB-106) | Systemic sclerosis | H1 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList